Evidence map›Paper›PMID 35280512›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Shuai Lin, Qianwen Sheng, Xiaobin Ma, Shanli Li, Peng Xu, Cong Dai, Meng Wang, Huafeng Kang, Zhijun Dai

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shuai LinDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Qianwen ShengDepartment of Oncology, Xi'an International Medical Center Hospital, Xi'an, China.
Xiaobin MaDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Shanli LiDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Peng XuDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Cong DaiDepartment of Thyroid Breast Surgery, Xi'an International Medical Center Hospital, Xi'an, China.
Meng WangDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Huafeng KangDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.ORCID https://orcid.org/0000-0002-0379-530X
Zhijun DaiDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.ORCID https://orcid.org/0000-0001-5209-8626
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) seriously endangers humans. In traditional Chinese medicine,

Identifiers

PMID35280512
PMCPMC8916871
OpenAlexW4220907989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.